Linked Data API

Show Search Form

Search Results

1521761
registered interest false more like this
date less than 2022-10-13more like thismore than 2022-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Non-tuberculous Mycobacteria: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of access to innovative treatments for people living with non-tuberculosis mycobacteria in the UK. more like this
tabling member constituency Birmingham, Selly Oak more like this
tabling member printed
Steve McCabe more like this
uin 62682 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-08-22more like thismore than 2023-08-22
answer text <p>On 20 October 2022, NHS England published clinical commissioning policy on the use of nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease NTMPD, following an independent review. NHS England concluded that there was enough evidence to make the treatment available.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-08-22T08:06:30.753Zmore like thismore than 2023-08-22T08:06:30.753Z
answering member
4423
label Biography information for Will Quince more like this
previous answer version
25107
answering member constituency Sleaford and North Hykeham more like this
answering member printed Dr Caroline Johnson more like this
answering member 4592
tabling member
298
label Biography information for Steve McCabe more like this